The Challenges of Predicting Drug-Induced QTc Prolongation in Humans

Author:

Valentin Jean-Pierre1,Hoffmann Peter2,Ortemann-Renon Catherine3,Koerner John4,Pierson Jennifer5ORCID,Gintant Gary6ORCID,Willard James4,Garnett Christine4,Skinner Matthew7,Vargas Hugo M8,Wisialowski Todd9,Pugsley Michael K10

Affiliation:

1. Department of Investigative Toxicology, UCB Biopharma SRL, Braine-l’Alleud B-1420, Belgium

2. Independent, Beaufort, South Carolina 29901, USA

3. Sanofi, Translational Medicine and Early Development, Bridgewater, New Jersey 08807, USA

4. Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland 20993, USA

5. Health and Environmental Sciences Institute, Washington, District of Columbia 20005, USA

6. AbbVie, Abbott Park, Illinois 60044, USA

7. Vivonics Preclinical Ltd, Nottingham SK10 4TG, UK

8. Department of Safety Pharmacology & Animal Research Center, Amgen, Thousand Oaks, California 91320, USA

9. Department of Safety Pharmacology, Pfizer, Groton, Connecticut 06340, USA

10. Department of Toxicology, Cytokinetics, South San Francisco, California 94080, USA

Abstract

Abstract The content of this article derives from a Health and Environmental Sciences Institute (HESI) consortium with a focus to improve cardiac safety during drug development. A detailed literature review was conducted to evaluate the concordance between nonclinical repolarization assays and the clinical thorough QT (TQT) study. Food and Drug Administration and HESI developed a joint database of nonclinical and clinical data, and a retrospective analysis of 150 anonymized drug candidates was reviewed to compare the performance of 3 standard nonclinical assays with clinical TQT study findings as well as investigate mechanism(s) potentially responsible for apparent discrepancies identified. The nonclinical assays were functional (IKr) current block (Human ether-a-go-go related gene), action potential duration, and corrected QT interval in animals (in vivo corrected QT). Although these nonclinical assays demonstrated good specificity for predicting negative clinical QT prolongation, they had relatively poor sensitivity for predicting positive clinical QT prolongation. After review, 28 discordant TQT-positive drugs were identified. This article provides an overview of direct and indirect mechanisms responsible for QT prolongation and theoretical reasons for lack of concordance between clinical TQT studies and nonclinical assays. We examine 6 specific and discordant TQT-positive drugs as case examples. These were derived from the unique HESI/Food and Drug Administration database. We would like to emphasize some reasons for discordant data including, insufficient or inadequate nonclinical data, effects of the drug on other cardiac ion channels, and indirect and/or nonelectrophysiological effects of drugs, including altered heart rate. We also outline best practices that were developed based upon our evaluation.

Funder

The HESI Cardiac Safety Committee Proarrhythmia Working Group is supported by sponsorships from member companies

HESI’s corporate sponsors

Publisher

Oxford University Press (OUP)

Subject

Toxicology

Reference164 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3